HMGCR and prostate cancer: In turn, when the significance of s12916 HMGCR was assessed in men with prostate cancer (n = 22,773), compared to control (n = 23,050), the studied relationship was relatively small (OR 0.97; 95% CI 0.94–1.00; p = 0.003) and did not correlate with the advancement of proliferative changes [118].